



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Hepatitis C Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, Diagnosis.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Does the patient have a diagnosis of chronic Hepatitis C with documented genotyping?

Yes No

Q2. Is documentation of the diagnosis and genotype attached to this request?

Yes No

Q3. Is the prescribed dose and length of therapy consistent with FDA-approved labeling or peer-reviewed medical literature?

Yes No

Q4. Is the requested drug age-appropriate for the patient according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed literature?

Yes No

Q5. Is the patient actively abusing alcohol or IV drugs, or has a history of abuse?

Yes No

Q6. Has prescriber counseling regarding the risks of alcohol or IV drug abuse and an offer of a referral for substance use disorder treatment been completed?

Yes No

Q7. Has documentation of prescriber counseling regarding the risks of alcohol or IV drug abuse and an offer of a referral for substance use disorder treatment attached to this request?



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Hepatitis C Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Form containing 18 questions (Q8-Q18) regarding hepatitis C agents, each with Yes/No checkboxes.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above.



HEALTH PARTNERS PLANS  
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Hepatitis C Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q19. Is the patient negative for hepatitis B sAb?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q20. Has a hepatitis B immunization plan or counseling to receive the hepatitis B immunization series been completed? Note: The prescriber must submit documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q21. Has documentation for the treatment plan and patient counseling attached to this request?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q22. Has the patient had an HIV screening (HIV Ag/Ab)? Note: The prescriber must submit documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q23. Has documentation for the HIV screening attached to this request?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q24. Is the patient HIV-positive confirmed positive by HIV-1/HIV-2 differentiation immunoassay?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q25. Is the patient being treated for HIV?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q26. Is there documented rationale for the beneficiary for the patient not being treated? Note: The prescriber must submit documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q27. Is documented rationale attached to this request?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q28. Does the patient meet both of the following? A) Has documentation of AASLD-recommended resistance-associated substitution (RAS) testing and B) The patient is being prescribed a drug regimen in accordance with AASLD guidance?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q29. Is documentation supporting the RAS testing been attached to this request?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q30. Is the patient genotype 1a or had a previous treatment failure with a direct-acting antiretroviral (DAA) regimen?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS  
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Hepatitis C Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.**

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q31. Is the patient prescribed an AASLD recommended drug regimen based on the documented results of a NS5A RAS screening?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q32. Does the patient have a life expectancy of less than 12 months due to non-liver-related comorbid conditions?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q33. Has a documented quantitative HCV RNA at baseline that was tested within the past 3 months? Note: The prescriber must submit documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q34. Is documentation supporting the HCV RNA testing attached to this request?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q35. Does the patient have a history of non-adherence?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q36. Has the causes of non-adherence to a previously prescribed hepatitis C treatment regimen been corrected or addressed?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q37. Have all potential drug interactions been addressed by the prescriber (such as discontinuation of the interacting drug, dose reduction of the interacting drug, or counseling of the beneficiary of the risks associated with the use of both medications when they interact)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q38. Is the patient prescribed ribavirin?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q39. Does the patient have a pretreatment hemoglobin of at least 10 g/dL?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q40. Is the patient female?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q41. Does the patient meet ALL of the following? A) The patient had a negative pregnancy test immediately prior to initiating therapy, B) The patient will use two or more forms of contraception, and C) The patient will have monthly pregnancy tests during therapy.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Hepatitis C Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q42. Is the request for a non-preferred agent?
Q43. Does the patient have a history of therapeutic failure, contraindication, or intolerance to the preferred Hepatitis C Agents appropriate for the beneficiary's genotype according to peer-reviewed medical literature?
Q44. Is the patient currently receiving treatment with the same non-preferred Hepatitis C Agent?
Q45. Does the patient have a documented commitment to adherence with the planned course of treatment and mutual prescriber and Departmental monitoring?
Q46. Has documentation supporting the adherence commitment been attached?
Q47. Additional Information:

Prescriber Signature

Date

Updated for 2020